901 results on '"Preusser M"'
Search Results
2. Prognosticators of survival in patients with metastatic pancreatic cancer and ascites
3. 192P Analysis of tumor-associated macrophages and tumor-infiltrating lymphocytes within the tumor microenvironment of primary tumors and matched brain metastases
4. 18P Association of DNA methylation profiles with pathologic complete response in early triple-negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
5. PB0919 High Rates of Bleeding in Unselected Patients with Cancer: Results from a Prospective Cohort Study
6. OC 46.5 Tissue Factor Pathway Inhibitor is Associated with Risk of Venous Thromboembolism and All-Cause Mortality in Patients with Cancer
7. OC 46.4 Association of Growth Differentiation Factor-15 (GDF-15) with Thromboembolism and Mortality in Patients with Cancer: Findings from the Vienna Cats Study
8. Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
9. Clinical risk factors for ascites in metastatic pancreatic cancer
10. Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
11. Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer
12. 1236P Comorbidities and their association with the overall survival in a large European cohort with gastroesophageal cancer
13. OS03.5.A Characterization of the inflammatory tumor microenvironment composition in solid cancer patients with brain metastases after progression to immune checkpoint inhibitor therapy
14. P09.03.A Associations of levetiracetam use with the safety and tolerability of chemoradiotherapy for patients with newly diagnosed glioblastoma
15. OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd): A biomarker analysis from the TUXEDO-1 trial
16. 288MO Brain-only oligometastatic cancer patients present with longer overall survival than patients with extracranial involvement
17. P15.03.A The value of 7 Tesla MR spectroscopic imaging for improved preoperative determination of the tumor grade and IDH status in gliomas: preliminary data
18. P11.27.B Whole genome DNA methylation as predictive biomarker in CNS WHO grade 2 and 3 oligodendroglioma patients receiving early postoperative treatment
19. 1242P Thromboembolic events and their association with the overall survival in a large European cohort with gastroesophageal cancer
20. P11.23.B Neurological symptoms independently associate with overall survival in patients with melanoma brain metastases
21. P11.18.A Localizing value of EEG recordings in patients with glioblastoma
22. OS03.7.A Clinical characteristics, treatment and long-term outcome of patients with brain metastases from thyroid cancer - an analysis of the Vienna Brain Metastasis Registry
23. P11.55.B Postoperative MRI is able to detect an unexpected residual tumor after surgery of brain metastases: experience from 5 specialized centers
24. 286MO Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma
25. 45P Monocyte subpopulations and myeloid-derived suppressor cells in peripheral blood of cancer patients receiving immune checkpoint inhibition-based treatment
26. JS07.4.A Correspondence of glutamine and glycine imaging based on 7T MRSI to amino acid PET
27. 307P Incidence of neurological symptoms in brain metastases from breast cancer and its impact on prognosis: An analysis of 968 patients with brain metastases
28. Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
29. P-175 Local inflammatory biomarkers and their association with systemic inflammation as well as overall survival in primary metastatic gastroesophageal cancer patients
30. Introducing pro and con discussions in ESMO Open—Cancer Horizons
31. 165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
32. PO-03: Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer
33. Use of Neuroimaging Techniques in Glioma Patients – Results of an International Survey on behalf of the EORTC Brain Tumor Group
34. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
35. 1400P Initial symptoms and their association with survival in patients with stage II-III gastroesophageal adenocarcinoma
36. 343MO Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma
37. 369P Characterization of the inflammatory tumor microenvironment composition in brain metastases after failure of immune checkpoint inhibitor therapy
38. 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
39. 1774P Exploration of torque teno virus (TTV) levels as marker for immune suppression during systemic therapy in advanced solid cancer patients
40. P14.49 Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey
41. OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials
42. P14.14 Adjuvant treatment versus initial observation in newly diagnosed WHO grade II and grade III oligodendroglioma: real-life data from two academic, tertiary care centers in Austria
43. 1428P Circulating nutritional biomarkers and their association with survival in patients with metastatic gastroesophageal cancer
44. P14.03 Shifting trends and entity-specific aspects in patients with brain metastasis: real-life analysis from 6031 individuals over an observation period of 30 years
45. 345MO Treatment associated changes in the inflammatory microenvironment composition of brain metastases
46. Case-Based Review: meningioma.
47. P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis
48. Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
49. PO-92 Evaluation of gemcitabine and platinum agents for the prediction of venous thromboembolism in patients with cancer: results from the Vienna Cancer and thrombosis Study
50. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.